Development of Memesto, a wearable repetitive message and music therapy device that senses and reduces agitation in persons with AD/ADRD.

开发 Memesto，一种可穿戴式重复信息和音乐治疗设备，可感知并减少 AD/ADRD 患者的躁动。

• 批准号: 10322846
• 负责人: Jeffery Banker
• 金额: $ 50万
• 依托单位: EDGEWATER SAFETY SYSTEMS LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10322846
• 关键词: Address; Aftercare; Age; Aggressive behavior; Agitation; Alzheimer' s Disease; Alzheimer' s disease diagnostic; Alzheimer' s disease related dementia; American; Antipsychotic Agents; Anxiety; Assisted Living Facilities; Base of the Brain; Behavior; Behavioral; Biological Markers; Biometry; Caregivers; Cellular Phone; Clinical Trials; Collaborations; Data; Dementia; Detection; Development; Devices; Diagnostic; Disinhibition; Disorientation; Eating; Effectiveness; Elements; Equipment and supply inventories; Family; Family psychotherapy; Feedback; Friends; Goals; Health; Health care facility; Home; Impaired cognition; Individual; Intervention; Knowledge; Legal patent; Lewy Body Dementia; Medical Device; Memory Loss; Music; Music Therapy; Nerve Degeneration; Neurodegenerative Disorders; Notification; Nursing Homes; Online Systems; Outcome; Participant; Patient Monitoring; Patients; Persons; Pharmaceutical Preparations; Phase; Physical Function; Play; Population Heterogeneity; Problem behavior; Pulse Rates; Quality of life; Reporting; Safety; Sales; Schedule; Self Care; Site; Small Business Innovation Research Grant; Stress; Surveys; System; Techniques; Technology; Testing; Therapeutic; Time; Voice; Water; base; brain pathway; burnout; caregiver interventions; cognitive function; commercial application; decision-making capacity; dementia care; design; detection platform; direct patient care; effectiveness evaluation; efficacy testing; experience; follow-up; improved; innovation; miniaturize; neuropsychiatry; next generation; open label; operation; phase 1 study; preservation; programs; prototype; residential care facility; sensor; success; voice therapy; wearable device; wearable sensor technology; web app

PROJECT SUMMARY Alzheimer’s Disease and Related Dementias (AD/ADRD) are age-associated neuro-degenerative diseases characterized by memory loss, disorientation, and reduced decision-making capacity and self-care. 70% of the 7.2+ million Americans with AD/ADRD experience problematic agitation that includes aggression, combativeness, shouting, exit-seeking and disinhibition. An urgent need exists for interventions that improve health outcomes for these individuals. Utilizing findings that familiar-voice-based brain pathways and reminiscent music are preserved until very late stage ADRD, Edgewater Safety Systems developed a smart wearable media player (Memesto) that family and other caregivers could use with a web app to record, schedule and deliver voice and music to an ADRD patient through this device. Caregivers were able to record greetings, reminders to take medication, drink water or eat lunch, and these messages could be played for the patient via the device at set dates and times. In a follow-up survey with caregivers who used the Memesto with patients at care facilities, 11 of 11 rated it 4.5 out of 5 for “usefulness in mitigating agitation.” Edgewater proposes to develop a more innovative wearable device that senses rising agitation in the patient and automatically plays therapeutic messages and music shown to have had the greatest success reducing or eliminating agitation in the wearer’s previous episodes. With this next generation Memesto, Edgewater aims to improve quality of life for a diverse population of ADRD persons; diminish the use of potentially harmful drugs as an intervention; and help reduce stress and burnout in caregivers. The new Memesto will have four key elements of innovation: 1) repetitive, programmable voice and music therapy in a wearable device, a first for AD/ADRD care; 2) web-based app that enables family and friends to deliver personal messages and music anytime; 3) agitation-sensing system that reads biometric data from non-invasive body-worn sensors to automatically deploy media therapy; and 4) sensor data taken at start and end of the played media to determine effectiveness of that media in reducing agitation and continually prioritize the most effective media. In the Phase I study, Edgewater will partner with Rush Alzheimer’s Disease Center to: 1) carry out a 10-week clinical trial on 20 ADRD persons to gather quantitative evidence of the original audio player’s effectiveness at reducing agitation; and 2) demonstrate feasibility of ADRD agitation detection and automated intervention. Phase II will focus on complete implementation of a fully automated, miniaturized, wearable Memesto device and a broad field trial testing efficacy of the new agitation sensing and automated intervention system. The Alzheimer's Disease Diagnostics and Therapeutics market reached $7.5 billion in 2018, with a projection of $11.1 billion by 2024. There is a pool of 5 million U.S. ADRD sufferers who experience agitation who would benefit from the proposed agitation management system.

项目摘要 阿尔茨海默氏病和相关痴呆症（AD/ADRD）是与年龄相关的神经脱生性疾病 以记忆力丧失，迷失方向以及减少决策能力和自我保健为特征。 70％ 72多百万的美国人有广告/ADRD经验有问题的激动，包括侵略， 战斗，大喊，寻求出口和抑制。迫切需要进行改善的干预措施 这些人的健康成果。利用发现基于熟悉的大脑通道和 保留了让人联想的音乐，直到非常晚期的ADRD，Edgewater安全系统开发了一个聪明的 可穿戴媒体播放器（MEMESTO），家人和其他护理人员可以与Web应用程序一起录制， 通过此设备安排并向Adrd患者提供语音和音乐。看护人能够记录 问候，提醒服药，喝水或吃午餐，这些信息可以播放 通过设备在设定日期和时间进行患者。在对使用Memesto的护理人员的后续调查中 护理设施的患者中，11个中的11个评价为4.5，满分5分，以“减轻搅拌的用处”。 edgewater 提出开发一种更具创新性可穿戴设备的提议，该设备感受到患者的搅动不断上升 自动播放热信息和音乐表现为最大的成功或 消除佩戴者以前的情节中的搅动。有了下一代的模因，Edgewater的目标是 改善ADRD多样性人群的生活质量；减少使用潜在有害药物的使用 作为一种干预；并有助于减轻护理人员的压力和倦怠。新的记忆将有四个钥匙 创新元素：1）可穿戴设备中的重复，可编程的语音和音乐疗法，第一个 广告/adrd护理； 2）基于网络的应用程序，使家人和朋友能够传递个人信息和音乐 随时； 3）搅动感应系统，该系统读取了从非侵入性身体传感器到的生物识别数据 自动部署媒体疗法； 4）在播放媒体的一开始和结尾获取的传感器数据 确定该媒体在减少搅动并不断优先考虑最有效的媒体方面的有效性。 在第一阶段的研究中，Edgewater将与Rush Alzheimer的疾病中心合作：1）进行10周 对20名Adrd人的临床试验，以收集原始音频播放器有效性的定量证据 减少搅动； 2）证明了ADRD搅动检测和自动干预的可行性。 第二阶段将着重于完整实施全自动，微型，可穿戴的内存设备 以及新的搅动感应和自动干预系统的广泛现场试验效率。 阿尔茨海默氏病诊断和治疗药市场在2018年达到75亿美元，预测 到2024年，有111亿美元。有一个500万美国add的患者会经历激动人心的人 拟议的搅动管理系统受益。